跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
張 鴻猷
專案助理教授
醫學系內科學科
電子郵件
amadeus0814
ym.edu
tw
h-index
h10-index
h5-index
1610
引文
23
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
711
引文
14
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
491
引文
11
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2009
2024
每年研究成果
概覽
指紋
網路
研究成果
(79)
類似的個人檔案
(6)
指紋
查看啟用 Hung-Yu Chang 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Ablation
27%
All-cause Mortality
12%
Angiotensin
10%
Angiotensin Receptor-neprilysin Inhibitor
16%
Atrial Arrhythmia
19%
Atrial Fibrillation
91%
Atrial Fibrillation Ablation
23%
Atrial Flutter
10%
Atrial Substrate
16%
Atrium
11%
Baseline Characteristics
13%
Cardiac Autonomic Function
10%
Cardiac Resynchronization Therapy
12%
Cardiovascular Mortality
19%
Cardiovascular Outcomes
11%
Catheter Ablation
82%
CHA2DS2-VASc Score
12%
Clinical Efficacy
10%
Clinical Outcomes
29%
Confidence Interval
15%
Cost-effectiveness Evaluation
10%
Ganglionated Plexi
16%
Health Systems
10%
Heart Disease Diagnosis
11%
Heart Failure
45%
Heart Failure Hospitalization
26%
Heart Failure Patients
44%
Heart Failure Treatment
15%
Heart Failure with Preserved Ejection Fraction (HFpEF)
67%
Heart Rate
11%
Heart Transplantation
14%
Hospitalization
11%
Ivabradine
23%
Left Atrial
15%
Left Ventricular Ejection Fraction
27%
Non-paroxysmal Atrial Fibrillation
17%
Paroxysmal Atrial Fibrillation
11%
Patients with Heart Failure
35%
Real-world Experience
10%
Reduced Ejection Fraction
56%
Sacubitril-valsartan
66%
Sleep Apnea Detection
10%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
13%
Substrate Properties
12%
Sudden Cardiac Death
10%
Superior Vena Cava
24%
Systolic Heart Failure
10%
Taiwan
44%
Taiwan Society of Cardiology
34%
Taiwanese
10%
Medicine and Dentistry
Ablation
85%
All Cause Mortality
8%
Angiotensin
10%
Angiotensin Receptor
16%
Antiarrhythmic Agent
7%
Apoplexy
8%
Atrial Fibrillation
100%
Atrial Flutter
15%
Atrioventricular Nodal Reentry Tachycardia
6%
Atrium
11%
Cardiac Resynchronization Therapy
12%
Cardiology
36%
Cardiovascular Risk
7%
Cardiovascular System
13%
CHA2DS2-VASc Score
6%
CHADS2 Score
6%
Chronic Kidney Disease
9%
Combination Therapy
14%
Congestive Heart Failure
92%
Cost-Effectiveness Analysis
14%
Diabetes
10%
Ejection Fraction
42%
Electrocardiogram
10%
Electrocardiography
15%
Electrography
10%
Enkephalinase Inhibitor
12%
Glycon
9%
Hazard Ratio
8%
Health Care Cost
16%
Heart Failure with Reduced Ejection Fraction
49%
Heart Left Ventricle Ejection Fraction
12%
Heart Surgery
6%
Heart Transplantation
13%
Ivabradine
11%
Mortality Rate
10%
Paroxysmal Atrial Fibrillation
10%
Persistent Atrial Fibrillation
8%
Prevalence
9%
Pulmonary Vein Isolation
8%
Recurrent Disease
25%
Sacubitril
35%
Sodium Glucose Cotransporter 2 Inhibitor
8%
ST Segment Elevation Myocardial Infarction
10%
Sudden Cardiac Death
7%
Sudden Death
6%
Superior Vena Cava
20%
Supraventricular Tachycardia
7%
Systolic Heart Failure
10%
Tachyarrhythmia
16%
Valsartan
35%
